[Reirradiation for head and neck squamous cell carcinoma: Indications and results].

Réirradiations des carcinomes épidermoïdes des voies aérodigestives supérieures : indications et résultats.

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 14 06 2019
accepted: 08 07 2019
pubmed: 28 8 2019
medline: 9 10 2019
entrez: 28 8 2019
Statut: ppublish

Résumé

Despite progress in the management of head and neck squamous cell carcinoma (HNSCC), a significant proportion of patients previously irradiated for head-and-neck cancer will develop locoregional recurrence or a second primary. Because of the heterogeneity of this population with respect to disease-related factors (localization, volume, recurrence or second primary, time interval from previous irradiation…) and patient-related factors (comorbidities, sequelae of previous irradiation…), the optimal reirradiation treatment remains to be defined. Salvage therapy using reirradiation, despite some encouraging results, has historically been avoided because of concerns regarding toxicity. The results of more recent studies using contemporary treatment techniques and conformal delivery methods such as intensity modulated radiation therapy (IMRT) or stereotactic radiotherapy (SBRT) have been somewhat more promising. The aim of this review is to discuss the reirradiation of HNSCC in terms of patient selection and modern radiotherapy techniques.

Identifiants

pubmed: 31451359
pii: S1278-3218(19)30323-3
doi: 10.1016/j.canrad.2019.07.147
pii:
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

559-564

Informations de copyright

Copyright © 2019 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

J Biau (J)

Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63011 Clermont-Ferrand, France; Inserm, U1240 IMoST, université Clermont-Auvergne, 63011 Clermont-Ferrand, France. Electronic address: Julian.biau@clermont.unicancer.fr.

J Moreau (J)

Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63011 Clermont-Ferrand, France.

P Blanchard (P)

Département de radiothérapie, Gustave-Roussy cancer campus, 94800 Villejuif, France; Unité Inserm 1018 CESP, université Paris-Saclay, 94800 Villejuif, France.

J Thariat (J)

Département de radiothérapie, centre François-Baclesse, 14000 Caen, France; Laboratoire de physique corpusculaire IN2P3/ENSICAEN, UMR6534, Unicaen, Normandie université, 14000 Caen, France.

J Miroir (J)

Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63011 Clermont-Ferrand, France.

M Lapeyre (M)

Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63011 Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH